By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Invivoscribe announced on Tuesday a collaboration with Novartis to develop a companion diagnostic for acute myeloid leukemia patients.

The test will be for the identification of FLT3-positive AML patients for treatment with Novartis' midostaurin, or PKC412, a targeted small molecule inhibitor of FLT3 tyrosine kinase. The drug is currently in Phase III clinical development for newly diagnosed patients with FLT3 mutated AML.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.